Malignant neoplasm of stomach
|
0.700 |
Biomarker
|
disease |
BEFREE |
FGFR inhibitors may function against FGFR2-amplified GC, and a novel FGFR2-ACSL5 fusion identified by transcriptomic characterization may underlie clinically acquired resistance.
|
28122360 |
2017 |
Malignant neoplasm of stomach
|
0.700 |
Biomarker
|
disease |
BEFREE |
A similar incidence of FGFR2 amplification was found in Asian and UK GCs and was associated with lymphatic invasion and poor prognosis.
|
24457912 |
2014 |
Malignant neoplasm of stomach
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
As a well-defined antagonist in FGFR2-induced RAS/ERK activation, ectopic expression of sprouty (SPRY) family was reported in several kinds of cancers except gastric cancer.
|
28002800 |
2017 |
Malignant neoplasm of stomach
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
FGFR2 gene is preferentially amplified and overexpressed in diffuse-type gastric cancer.
|
16773196 |
2006 |
Malignant neoplasm of stomach
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
KGFR expression tended to correlate with a good prognosis in gastric cancer.
|
16391783 |
2006 |
Malignant neoplasm of stomach
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Approximately 5%-10% of gastric cancers have a fibroblast growth factor receptor-2 (FGFR2) gene amplification.
|
29177434 |
2017 |
Malignant neoplasm of stomach
|
0.700 |
Biomarker
|
disease |
BEFREE |
The aim of the present study was to explore the effects of miR‑494 and FGFR2 in regulation of cancer‑initiating cell phenotypes and therapeutic efficiency of lapatinib in HER2‑positive gastric cancer.
|
29786108 |
2018 |
Malignant neoplasm of stomach
|
0.700 |
Biomarker
|
disease |
BEFREE |
Fibroblast growth factor receptor-2 (<i>FGFR2</i>) gene is amplified in up to 15% of patients with gastric cancer (GC).
|
31258762 |
2019 |
Malignant neoplasm of stomach
|
0.700 |
Biomarker
|
disease |
BEFREE |
FGFR2 in gastric cancer: protein overexpression predicts gene amplification and high H-index predicts poor survival.
|
27230412 |
2016 |
Malignant neoplasm of stomach
|
0.700 |
Biomarker
|
disease |
BEFREE |
FGFR1 is relatively frequently amplified and overexpressed in breast and lung cancer, and FGFR2 in gastric cancer.
|
27245147 |
2016 |
Malignant neoplasm of stomach
|
0.700 |
Biomarker
|
disease |
BEFREE |
Applying dual-colour FISH on 137 gastric tumours (89 FFPE surgical resections and 48 diagnostic biopsies), we observed FGFR2 amplification in 7.3% and HER2 amplification in 2.2% of GCs.
|
25086186 |
2014 |
Malignant neoplasm of stomach
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
Subgroup analysis revealed that high fibroblast growth factor receptor 2 expression was also associated with poor prognosis of gastric cancer, hepatocellular carcinoma, and esophageal cancer, but not correlated with pancreatic cancer.
|
28618942 |
2017 |
Malignant neoplasm of stomach
|
0.700 |
Biomarker
|
disease |
BEFREE |
Amplifications of certain RTKs (c-Met, FGFR2 and ErbB2) have been associated with human gastric cancer progression.
|
20331976 |
2010 |
Malignant neoplasm of stomach
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
Evaluation of Fibroblast Growth Factor Receptor 2 Expression, Heterogeneity and Clinical Significance in Gastric Cancer.
|
26516773 |
2015 |
Malignant neoplasm of stomach
|
0.700 |
Biomarker
|
disease |
BEFREE |
In conclusion, CD44 and FGFR2 maintain stemness in gastric cancer by differentially regulating c-Myc transcription.
|
27107424 |
2016 |
Malignant neoplasm of stomach
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
The FGFR2-inhibitory activity of PRO-007 was confirmed in genetically modified GC cell lines.
|
31396354 |
2019 |
Malignant neoplasm of stomach
|
0.700 |
Biomarker
|
disease |
BEFREE |
It will be clinically valuable to investigate the involvement of RTK-mediated signaling in intrinsicor acquired resistance to FGFR2 TKIs in GC.
|
25576915 |
2015 |
Malignant neoplasm of stomach
|
0.700 |
Biomarker
|
disease |
BEFREE |
The in vivo models established using SGC cell lines are expected to serve as a useful tool for the development of drugs such as FGFR2 inhibitors, TβR inhibitors, and CXCR1 inhibitors, which might be promising as SGC treatments.
|
29876827 |
2018 |
Malignant neoplasm of stomach
|
0.700 |
Biomarker
|
disease |
BEFREE |
Using a three-dimensional organoid tissue model, we functionally validated the metastatic potential of an FGFR2 amplification in gastric cancer.
|
28629429 |
2017 |
Malignant neoplasm of stomach
|
0.700 |
Biomarker
|
disease |
BEFREE |
Deep-sequencing of a primary tumor and metastasis from a single patient, and functional validation in culture, reveals that TGFBR2 and FGFR2 act as drivers of gastric cancer.
|
25222187 |
2014 |
Malignant neoplasm of stomach
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
Clinical significance of keratinocyte growth factor and K-sam gene expression in gastric cancer.
|
23545898 |
2013 |
Malignant neoplasm of stomach
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
The correlations between anti-tumour sensitivity and the molecular segments of HER2, MET and FGFR2 alterations were further tested in a panel of GC cell lines and the patient-derived GC xenograft (PDGCX) model using the targeted inhibitors.
|
24518603 |
2014 |
Malignant neoplasm of stomach
|
0.700 |
Biomarker
|
disease |
BEFREE |
Inhibitors of FGFR2 or Erbb3 signaling may have therapeutic efficacy in the subset of gastric cancers containing FGFR2 amplification.
|
18381441 |
2008 |
Malignant neoplasm of stomach
|
0.700 |
Biomarker
|
disease |
BEFREE |
However, multivariate analysis indicated that FGFR2 amplification was not an independent prognostic factor for OS (HR=1.42, 95% CI: 0.77-2.61, p=0.261).Although FGFR2 amplification is associated with poorer OS, it does not appear to be an independent prognostic predictor in patients with advanced gastric cancer treated with palliative fluoropyrimidine and platinum chemotherapy.
|
27802183 |
2017 |
Malignant neoplasm of stomach
|
0.700 |
Biomarker
|
disease |
BEFREE |
FGFR2 Assessment in Gastric Cancer Using Quantitative Real-Time Polymerase Chain Reaction, Fluorescent In Situ Hybridization, and Immunohistochemistry.
|
25972329 |
2015 |